Page 60 - Medication Guide News Today

(0) Xywav demonstrated statistically significant differences in change in Epworth Sleepiness Scale score (p-value The safety profile in this study was consistent with the known safety profile of Xywav with no new safety signals observed in this population Company to host investor webcast today at 12:30 p.m. ET DUBLIN, April 20, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced positive results from the Phase 3 study of Xywav TM (calcium, magnesium, potassium, and so...

Incyte and MorphoSys AG: Incyte and MorphoSys Announce First Patient Dosed in Phase 3 inMIND Study Evaluating the Addition of Tafasitamab to Lenalidomide and Rituximab in Relapsed or Refractory Follicular or Marginal Zone Lymphoma Respiratory tract infection These are not all the possible side effects of MONJUVI. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. Before you receive MONJUVI, tell your healthcare provider about all your m...

MorphoSys AG: MorphoSys and Incyte Announce First Patient Dosed in Phase 3 inMIND Study Evaluating the Addition of Tafasitamab to Lenalidomide and Rituximab in Relapsed or Refractory Follicular or Marginal Zone Lymphoma Respiratory tract infection These are not all the possible side effects of MONJUVI. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. Before you receive MONJUVI, tell your healthcare provider about all your medical cond...

(diroximel fumarate) reinforce the treatment’s positive gastrointestinal tolerability profile Biogen advances leading research to help inform future patient management including new information on the clinical profile of extended interval dosing with natalizumab CAMBRIDGE, Mass., April 16, 2021 (GLOBE NEWSWIRE) — Biogen Inc. (Nasdaq: BIIB) today announced new data from its industry-leading portfolio of multiple sclerosis (MS) therapies to be presented at the American Academy of Neurology...

Search for: 5 Things To Know About This Relapsing Multiple Sclerosis (MS) Treatment That Comes In A Pill (Sponsored Post) 2.5 ® (ozanimod) If you have relapsing MS, finding treatment that works best for you means knowing what treatment options are out there. Discover a once-daily pill for people living with relapsing MS: ZEPOSIA ® (ozanimod) is a prescription medicine used to treat relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing...

(0) -- Primary study endpoint demonstrates 86 percent response rate for patients receiving co-therapy of KRYSTEXXA and mycophenolate mofetil -- Horizon Therapeutics plc (Nasdaq: HZNP) announced the publication of data from the first randomized controlled clinical trial (RCT) of KRYSTEXXA (pegloticase injection) concomitantly used with an immunomodulator, mycophenolate mofetil, in Arthritis Rheumatology [doi.org/10.1002/art.41731]. The Reducing Immunogenicity of Pegloticase (RECIPE) trial demon...

ABBVie  today announced that it has submitted applications seeking approval for SKYRIZI ® to the U.S. Food and Drug Administration and for SKYRIZI ® to the European Medicines Agency  for the treatment of adults with active psoriatic arthritis. 1 The submissions were supported by two pivotal Phase 3 studies, KEEPsAKE-1 and KEEPsAKE-2, which evaluated SKYRIZI in adults with active psoriatic arthritis including … ABBVie (NYSE: ABBV) today announced that it has submitted applications seeking...

Message : Required fields TYSABRI is a well-established high-efficacy treatment that now provides two routes of administration enabling flexibility to meet patients individual preferences and needs The subcutaneous option provides a shorter administration time and expands access to treatment for patients and physicians beyond the infusion setting The approval adds to Biogen’s strong MS portfolio and is part of its leading, innovative work to improve the understanding of optimal clinical outc...

Navigating MS Treatment During a Pandemic Sponsored Post (0) Crystal, a wife and mother of four, has been living with relapsing multiple sclerosis (MS) for nearly twenty years. Getting a proper diagnosis for her condition was not easy. She began struggling with fatigue, numbness, tingling, and pain in adolescence, but when she sought help for her symptoms in high school and college, her doctors didn’t take her complaints seriously. It was not until she fainted and ended up in the emerg...

ABBVie today announced that the New England Journal of Medicine has published 24-week results from the Phase 3 SELECT-PsA 1 trial evaluating RINVOQ ™ in adults with active psoriatic arthritis who had responded inadequately or were intolerant to one or more non-biologic disease modifying anti-rheumatic drugs . 1 These data build on previously announced Phase 3 topline results showing that upadacitinib 15 mg and 30 … ABBVie (NYSE: ABBV) today announced that the New England Journal of Medicine...